title: Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
abstract: Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival. The clinical manifestations of PMF include splenomegaly, consequent to extramedullary hematopoiesis, pancytopenias, and an array of potentially debilitating constitutional symptoms. The diagnosis is based on bone marrow morphology and clinical criteria. Mutations in the JAK2 (V617F), MPL (W515), and CALR (exon 9 indel) genes are found in approximately 90% of patients whereas the remaining 10% are so-called triple negatives. Activation of the JAK/STAT pathway results in overproduction of abnormal megakaryocytes leading to bone marrow fibrosis. These mutations might be accompanied by other mutations, such as ASXL1. The commonly used prognostication scoring for PMF is based on the International Prognostic Scoring System. The subsequently developed Dynamic International Prognostic Scoring System-plus employs clinical as well as cytogenetic variables. In PMF, CALR mutation is associated with superior survival and ASXL1 with inferior outcome. Patients with triple-negative PMF have a higher incidence of leukemic transformation and lower overall survival compared with CALR- or JAK2-mutant patients. The impact of genetic lesions on survival is independent of current prognostic scoring systems. These observations indicate that driver and passenger mutations define distinct disease entities within PMF. Accounting for them is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.
authors.affiliation: Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait.
authors.forename: Salem H
authors.initials: SH
authors.lastname: Alshemmari
authors.forename: Reshmi
authors.initials: R
authors.lastname: Rajan
authors.forename: Ashkan
authors.initials: A
authors.lastname: Emadi
mesh_terms: D037282:Calreticulin / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D007938:Leukemia / Q000150:complications; D009154:Mutation / Q000235:genetics*; D009857:Oncogenes; D055728:Primary Myelofibrosis / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D011379:Prognosis; D053628:Receptors, Thrombopoietin / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics
chemical_list: C473949:ASXL1 protein, human; D037282:Calreticulin; D053628:Receptors, Thrombopoietin; D012097:Repressor Proteins; C082218:MPL protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2